Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor

Masato Furuhashi; Megumi Matsumoto; Shinya Hiramitsu; Akina Omori; Marenao Tanaka; Norihito Moniwa; Hideaki Yoshida; Junnichi Ishii; Tetsuji Miura

doi:10.1371/journal.pone.0154482

Loading metrics

Open Access

Peer-reviewed

Research Article

Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor

Masato Furuhashi ,

* E-mail: furuhasi@sapmed.ac.jp

Affiliation Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo, 060-8543, Japan
⨯
Megumi Matsumoto,

Affiliation Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo, 060-8543, Japan
⨯
Shinya Hiramitsu,

Affiliation Hiramitsu Heart Clinic, Shiroshita-cho 2-35, Minami-ku, Nagoya, 457-0047, Aichi, Japan
⨯
Akina Omori,

Affiliation Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo, 060-8543, Japan
⨯
Marenao Tanaka,

Affiliation Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo, 060-8543, Japan
⨯
Norihito Moniwa,

Affiliation Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo, 060-8543, Japan
⨯
Hideaki Yoshida,

Affiliation Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo, 060-8543, Japan
⨯
Junnichi Ishii,

Affiliation Department of Joint Research Laboratory of Clinical Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
⨯
Tetsuji Miura

Affiliation Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo, 060-8543, Japan
⨯

Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor

Masato Furuhashi,
Megumi Matsumoto,
Shinya Hiramitsu,
Akina Omori,
Marenao Tanaka,
Norihito Moniwa,
Hideaki Yoshida,
Junnichi Ishii,
Tetsuji Miura

Published: April 28, 2016
https://doi.org/10.1371/journal.pone.0154482

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Glucose
Is the Subject Area "Glucose" applicable to this article?

Thanks for your feedback.
Type 2 diabetes
Is the Subject Area "Type 2 diabetes" applicable to this article?

Thanks for your feedback.
Cholesterol
Is the Subject Area "Cholesterol" applicable to this article?

Thanks for your feedback.
Adipocytes
Is the Subject Area "Adipocytes" applicable to this article?

Thanks for your feedback.
Glucose metabolism
Is the Subject Area "Glucose metabolism" applicable to this article?

Thanks for your feedback.
HbA1c
Is the Subject Area "HbA1c" applicable to this article?

Thanks for your feedback.
Insulin resistance
Is the Subject Area "Insulin resistance" applicable to this article?

Thanks for your feedback.
Lipolysis
Is the Subject Area "Lipolysis" applicable to this article?

Thanks for your feedback.